19 novembro de 2021
Skin barrier dysfunction plays a key role in atopic dermatitis (AD). This impairment is related to altered composition and metabolism of epidermal sphingolipids and a deficiency of ceramides. Glycosaminoglycans (GAGs), and especially hyaluronic acid, could be useful in the management of AD.
For decades following the recognition of atopic dermatitis (AD) as a common allergic skin disease of dogs, its treatment relied mainly on the use of oral — and more often than not injectable — glucocorticoids.
Canine atopic dermatitis (AD) is a complex inflammatory skin disease associated with cutaneous microbiome, immunological and skin barrier alterations.
Systemic antimicrobials are critically important in veterinary healthcare and resistance is a major concern.
The skin microbiome is a key component of pathogenesis in atopic dermatitis (AD). The skin of AD patients is characterized by microbial dysbiosis, with a reduction of microbial diversity and overrepresentation of pathogenic Staphylococcus aureus (S. aureus).
Atopic dermatitis (AD) is a common, chronic skin disorder affecting up to 2.4% of the worldwide population.
Prof Rita Carmona traz neste bate papo os principais pontos abordados congresso mundial de dermatologia veterinária de 2024 que aconteceu em Boston. Assista e fique por dentro das novidades.
Conhecendo a Barreira Cutânea
Ouça nosso podcast com a Dra. Marcella Braga: Quem é o atópico do bem?
Aqui você vai encontrar 2 palestras incríveis com Dra Silmara, Dr Pablo Manzuc e no final, tira dúvidas com a presença da Dra Silmara, Dr Pablo, Dra Larissa Botoni e Dra Wandrea Mendes.
Ouça nosso podcast com a Dra. Marcella Braga: Porque suplementar um paciente dermatopata
Este site usa cookies para fornecer a funcionalidade necessária do site, melhorar sua experiência e analisar nosso tráfego. Ao usar nosso site, você concorda com nossa Política de privacidade e uso de cookies.
